Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial; reports Q4 2024 net loss of $49.7M

PLIANT THERAPEUTICS, INC.

BEACON-IPF discontinued after DSMB and outside expert panel recommendation due to imbalance in IPF-related adverse events; early efficacy on FVC observed.
Q4 2024 net loss of $49.7M vs $41.1M in Q4 2023; R&D expenses increased to $38.8M from $33.2M.
Cash, cash equivalents, restricted cash and short-term investments of $357.2M as of Dec 31, 2024; sufficient for 12+ months.
Appointed Delphine Imbert, Ph.D. as Chief Technical Officer, previously at Chinook Therapeutics.
Phase 1 trial of PLN-101095 in solid tumors continues; interim data from first three dose cohorts expected Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.